Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
5
×
national blog main
biotech
boston blog main
fda
national top stories
new york top stories
boston top stories
new york blog main
san francisco top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
abbvie
acorda therapeutics
aimmune therapeutics
akcea therapeutics
allergy
alnylam pharmaceuticals
alprazolam
amgen
ampyra
anaphylaxis
andrew oxtoby
apokyn
apomorphine
barry greene
billy dunn
biogen
boston
boston university
boulder/denver blog main
boulder/denver top stories
cgrp inhibitors
chronic migraine
What
fda
friday
5
×
drug
approved
new
patients
approval
decades
late
medicine
oral
therapy
time
won
acorda
acute
addresses
agency
ago
aimmune
allergy
alnylam
approve
atrophy
awaits
awarded
biological
causes
condition
cope
crossed
daily
decision
developed
discovered
disease
eli
episodes
evrysdi
fingers
Language
unset
Current search:
friday
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision